Vitrolife AB (VITR.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

VITR.ST · Stock Price

SEK 107.40-50.80 (-32.11%)

Market Cap: $1.6B

Historical price data

Market Cap: $1.6BPipeline: 1 drugPatents: 1Founded: 1994HQ: Gothenburg, Sweden

Sector Ranking#29 in Diagnostics & Precision Medicine

Overview

Vitrolife AB is a Swedish public company and a dominant, fully integrated platform provider in the global assisted reproductive technology (ART) market. Founded in 1994, the company has evolved from a media specialist into a strategic partner for fertility clinics through a combination of organic innovation and strategic acquisitions, most notably of Igenomix. Its strategy focuses on offering complementary products and services across the entire IVF journey—from oocyte retrieval to embryo transfer and genetic testing—to improve success rates and lab efficiency, underpinned by a deep commitment to quality and clinical support.

Reproductive HealthFertility

Technology Platform

An integrated platform combining time-lapse embryo imaging (EmbryoScope), automated vitrification/warming (Gavi), proprietary culture media, genetic testing services (Igenomix), and lab management software (eWitness) to optimize the entire IVF workflow from oocyte to embryo transfer.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-li...	Culture Media	Pre-clinical

Funding History

1

IPOUndisclosedUndisclosedJun 15, 2001

Opportunities

The global IVF market is projected to surpass $40 billion by 2030, driven by delayed parenthood, rising infertility rates, and greater social acceptance.

Vitrolife is uniquely positioned to capture this growth through its integrated platform that addresses the entire treatment journey, with significant expansion potential in underpenetrated emerging markets like Asia and Latin America.

Risk Factors

Key risks include intense competition from large integrated rivals like CooperSurgical, potential pricing pressure on consumables, and regulatory or reimbursement changes affecting IVF and genetic testing services.

The company also faces execution risks related to integrating acquisitions and the inherent ethical and social scrutiny of the ART industry.

Competitive Landscape

Vitrolife's primary competitor is CooperSurgical, which offers a similarly broad portfolio. It also faces segment-specific competition from Merck KGaA in media, Esco Medical in time-lapse, and Natera in genetic testing. Vitrolife's key advantage is its deeply integrated ecosystem of instruments, media, and services, which creates high switching costs and workflow efficiencies for clinics.